Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories


NexImmune elects to launch initial public offering
Johns Hopkins University's oncology therapy developer NexImmune has filed to raise up to $86.3m in an IPO on the Nasdaq Global Market.
Bolt Biotherapeutics charges to IPO stage
Novo and Pfizer are among the investors set to exit the Stanford spinout, which has set a $100m target for its initial public offering.
OUI provides fourth quarter update
Oxford spinouts took in $350m in Q4 and OUI saw strong demand for its consulting services on the back of its covid-19 vaccine success.
Vor Biopharma goes for $150m in IPO
Columbia University is in line for an exit as cancer drug developer Vor files for its initial public offering.
Karslake slides into UChicago’s Polsky Center
Christine Karslake is set to lead UChicago’s Polsky Science Ventures unit and will be tasked with setting up a deep tech-focused accelerator.
US universities launch Academic Accelerator
Indiana University is among four US institutions selected by the US Department of Defense's open national security innovation programme for a new accelerator targeting applied research spinouts.
A1 Group acquires Invenium
The telecoms group has bought a 51% stake in its portfolio company Invenium, a mobility data analytics company spun out of TU Graz.
Ampacimon procures Diael in acquisition deal
The insulation breakage measuring device producer is joining Ampacimon having launched out of Polytechnic University of Madrid over ten years ago.

Other News

J-Pharma jacks series D up to $21m
Fidelity provided a $4.8m second tranche after a first close featuring vehicles for Kyushu University and Osaka University.
Biohaven brings Kleo into the fold
Existing shareholder Biohaven has agreed to purchase the remaining stake in Kleo Pharmaceuticals, a Yale spinout it first backed in 2016.
Atalanta attains series A
Atalanta Therapeutics has launched out of UMass with $110m in combined series A and partnership funding to develop therapies for neurodegenerative diseases.
Sana to seek $150m in IPO
Three years after launching to commercialise stem cell research from Harvard University, Sana has filed for an initial public offering.
USF's Sanberg to return to faculty research
USF's senior vice-president for research and innovation Paul Sanberg will return to being a distinguished professor in neurosurgery and brain repair.
Daily deal net: January 12, 2021
Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Editor's Picks

SETsquared: a global leader continues charging ahead
The world’s number one incubator has been making a big impact since 2002, having supported more than 4,000 entrepreneurs that have raised more than $2.2bn between them.
It’s not about the money
Lessons from the GUV Summit in Houston, Texas, this month
Big deal: Orchard harvests $200m IPO
Orchard Therapeutics has listed in the US following a $200m initial public offering that came just three years after the gene therapy developer was spun out of UCL.
UCL Technology Fund: an unparalleled approach to commercialisation
Editor Thierry Heles sits down with David Grimm (pictured), manager of the UCL Technology Fund, to find out what makes the fund unique among its UK and international peers.
test reg